These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9636582

  • 21. Impact of diltiazem administration and cyclosporine levels on the incidence of acute rejection in heart transplant patients.
    Delgado JF, Sánchez V, de la Calzada CS, Gómez-Sánchez MA, Escribano P, Cea-Calvo L, Pascual JG, de la Cámara AG, Sotelo T, Rufilanchas JJ.
    Transpl Int; 2003 Sep; 16(9):676-80. PubMed ID: 12783159
    [Abstract] [Full Text] [Related]

  • 22. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
    Klupp J, Bechstein WO, Pratschke J, Tullius SG, Gebhard A, Lobeck H, Langrehr JM, Neuhaus R, Neuhaus P.
    Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
    [No Abstract] [Full Text] [Related]

  • 23. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants.
    Foradori A, Mezzano S, Videla C, Pefaur J, Elberg A.
    Transplant Proc; 1998 Aug; 30(5):1685-7. PubMed ID: 9723244
    [No Abstract] [Full Text] [Related]

  • 24. Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
    Elkashab M, Reizig M, Greig PD, Cameron R, Phillips MJ, Chung S, Cattral M, Levy G.
    Transplant Proc; 1994 Oct; 26(5):2669-71. PubMed ID: 7940835
    [No Abstract] [Full Text] [Related]

  • 25. Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation.
    Dumont L, Chen H, Daloze P, Xu D, Garceau D.
    Transplantation; 1993 Jul; 56(1):181-4. PubMed ID: 8333040
    [Abstract] [Full Text] [Related]

  • 26. Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts.
    Lewis R, Coutee J, Steinmuller D, Hatch D, Manion S, Agrawal R, Moel D, Flanigan R.
    Transplant Proc; 1997 Jul; 29(1-2):294-5. PubMed ID: 9123002
    [No Abstract] [Full Text] [Related]

  • 27. Indications for mycofenolate mofetil therapy after liver transplantation.
    Platz KP, Mueller AR, Neuhaus P.
    Transplant Proc; 1997 Nov; 29(7):2880-1. PubMed ID: 9365601
    [No Abstract] [Full Text] [Related]

  • 28. Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: are milder immunosuppressive regimens advisable?
    Pascual J, Crespo M, Mateos ML, Marcén R, Orofino L, Burgos FJ, Liaño F, Ortuño J.
    Transplant Proc; 1998 Jun; 30(4):1329-30. PubMed ID: 9636540
    [No Abstract] [Full Text] [Related]

  • 29. Low incidence of acute cellular rejection in liver transplantation with Neoral.
    Imventarza O, Lendoire J, Bianco G, Saúl J, Braslavsky G, Trigo P, Cueto G, Duek F, Aziz H.
    Transplant Proc; 1998 Aug; 30(5):1854. PubMed ID: 9723307
    [No Abstract] [Full Text] [Related]

  • 30. More effective immunosuppression with the use of FK506 after liver transplantation.
    Lo CM, Fan ST, Liu CL, Ng IO, Lam BK, Yong BH, Lai CL, Lau GK, Wong J.
    Transplant Proc; 2000 Nov; 32(7):2269-70. PubMed ID: 11120161
    [No Abstract] [Full Text] [Related]

  • 31. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study.
    Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y, Lacidipine Study Group.
    Transplantation; 2004 Oct 27; 78(8):1204-11. PubMed ID: 15502721
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E, Remport A, Járay J, Máthé Z, Borka P, Perner F.
    Transplant Proc; 2001 May 27; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract] [Full Text] [Related]

  • 33. Optimal immunosuppressive clinical regimen in liver transplantation.
    Farges O, Samuel D, Bismuth H.
    Transplant Proc; 1994 Oct 27; 26(5):2676-8. PubMed ID: 7940838
    [No Abstract] [Full Text] [Related]

  • 34. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
    Platz KP, Mueller AR, Zytowski M, Bechstein WO, Blumhardt G, Lobeck H, Neuhaus P.
    Transplant Proc; 1995 Feb 27; 27(1):1111-3. PubMed ID: 7533357
    [No Abstract] [Full Text] [Related]

  • 35. Liver transplantation from cadaveric and living donors.
    Lo CM, Lo RJ, Lai CL, Fan ST, Wong J.
    Transplant Proc; 1996 Jun 27; 28(3):1659-60. PubMed ID: 8658826
    [No Abstract] [Full Text] [Related]

  • 36. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y, Takahara S, Kyo M, Ichimaru N, Toki K, Wang JD, Okuyama A.
    Transplant Proc; 1999 Jun 27; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract] [Full Text] [Related]

  • 37. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation.
    Hashikura Y, Kawasaki S, Matsunami H, Terada M, Ikegami T, Nakazawa Y, Watanabe M, Chisuwa H, Kamijima T, Takagi S, Makuuchi M.
    Transplant Proc; 1996 Apr 27; 28(2):1034-5. PubMed ID: 8623218
    [No Abstract] [Full Text] [Related]

  • 38. Correlation between Banff classification acute rejection scores and reversal of rejection.
    Park KK, Kim HC, Kwon JK, Park SB, Cho WH.
    Transplant Proc; 1998 Nov 27; 30(7):3067-8. PubMed ID: 9838351
    [No Abstract] [Full Text] [Related]

  • 39. Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration.
    Rodríguez JA, Crespo-Leiro MG, Paniagua MJ, Muñiz J, Hermida LF, Fojón S, Cuenca JJ, Juffé-Stein A, Castro-Beiras A.
    Transplant Proc; 1999 Sep 27; 31(6):2517-8. PubMed ID: 10500696
    [No Abstract] [Full Text] [Related]

  • 40. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP, Kowdley KV, Emond MJ, Barr D, Marsh CL, Carithers RL, Perkins JD.
    Clin Transplant; 1997 Aug 27; 11(4):328-33. PubMed ID: 9267724
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.